6
Participants
Start Date
April 27, 2017
Primary Completion Date
August 1, 2020
Study Completion Date
December 1, 2020
FATE-NK100
"Preparative regimen:~* Fludarabine 25 mg/m2 x 5 days start Day -6~* Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
University of Minnesota, Masonic Cancer Center, Minneapolis
Masonic Cancer Center, University of Minnesota
OTHER